Literature DB >> 26319226

Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism.

Davor Kust1, Ivan Kruljac2, Ana Šverko Peternac3, Jelena Ostojić4, Marin Prpić1, Dubravka Čaržavec5, Petar Gaćina5.   

Abstract

To best of our knowledge, this is the first reported case of pericardial and pleural effusions combined with ascites, precipitated with severe sunitinib-induced hypothyroidism. A 58-year-old man presented in our emergency department due to dyspnoea and dry cough. Sixteen months earlier, the patient underwent left nephrectomy due to metastatic renal cell adenocarcinoma (RCC), and therapy with sunitinib was initiated postoperatively. Thyroid function was not assessed during the therapy. On admission, all laboratory findings were within normal range. Computed tomography of the chest detected voluminous bilateral pleural effusions and mild pericardial effusion, and echocardiography revealed pericardial effusion. Thoracocentesis was carried out three times, and cytological examination showed no signs of malignant cells. After assessment of the thyroid function, neglected hypothyroidism was registered. Substitution therapy with levothyroxine was initiated, and thyroid function normalised 2 weeks later. Few days after the last thoracocentesis, his condition suddenly got worse. Thoracocentesis was repeated, and microbiological analysis of the exudate came positive for Klebsiella pneumoniae and Streptococcus pneumoniae. Despite the implemented therapeutic measures, his clinical condition progressively deteriorated. The patient died 27 days after the admission, hospital-acquired pneumonia was identified as the cause of death. Our case emphasises the necessity of careful monitoring and management of side-effects in patients who receive sunitinib. Hypothyroidism is a known cause of pleural, pericardial and abdominal effusions, as reported in several case reports. Timely initiation of substitution levothyroxine therapy can decrease unnecessary pauses in the therapy with sunitinib, as well as prevent development of severe symptoms.

Entities:  

Keywords:  Hypothyroidism; Pericardial effusion; Pleural effusion; Renal cell carcinoma; Sunitinib

Mesh:

Substances:

Year:  2016        PMID: 26319226     DOI: 10.1179/2295333715Y.0000000065

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

1.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

2.  Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.

Authors:  Adam Goldman; David Bomze; Rachel Dankner; Dana Fourey; Ben Boursi; Michael Arad; Elad Maor
Journal:  Target Oncol       Date:  2021-05-10       Impact factor: 4.493

3.  Increased Thyroid-Hormone Requirements Consistent With Type 3 Deiodinase Induction Related to Ibrutinib in a Thyroidectomized Woman.

Authors:  Alon Yehuda Mazori; Maria Skamagas
Journal:  AACE Clin Case Rep       Date:  2020-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.